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Abstract
Background: Stroke is one of the commonest causes of mortality in the world and anticipated to be an increasing
burden to the developing world. Stroke has a genetic basis and identifying those genes may not only help us
define the mechanisms that cause stroke but also identify novel therapeutic targets. However, large scale highly
phenotyped DNA repositories are required in order for this to be achieved.
Methods: The proposed Bio-Repository of DNA in Stroke (BRAINS) will recruit all subtypes of stroke as well as
controls from two different continents, Europe and Asia. Subjects recruited from the UK will include stroke patients
of European ancestry as well as British South Asians. Stroke subjects from South Asia will be recruited from India
and Sri Lanka. South Asian cases will also have control subjects recruited.
Discussion: We describe a study protocol to establish a large and highly characterized stroke biobank in those of
European and South Asian descent. With different ethnic populations being recruited, BRAINS has the ability to
compare and contrast genetic risk factors between those of differing ancestral descent as well as those who
migrate into different environments.
1. Background
Evidence shows that stroke incidence rates in developing
South Asian countries have increased by more than
100% during the last four decades, while they have
decreased by 42% in developed European countries over
the same time period [1]. Over a four-decade period,
stroke incidence rates increased from 52 per 100,000
person-years (1970-1979) to 117 per 100,000 person-
years (2000-2008) and at this rate stroke is expected to
become one of the major causes of death in South Asia
[1]. While much of this increase may be attributed to
changing lifestyles, a high percentage of all strokes
occur without any obvious aetiological cause suggesting
additional factors that contribute to the stroke risk
variability between ethnic groups. The ethnic differences
may arise due to varying lifestyles, differences in medical
treatment or the inherent genetic makeup.
Dissecting the genetic causes of a complex disorder
such as stroke and estimating their relative attributable
risks, necessitates a large study cohort in-order to pro-
vide sufficient power to the analysis. Herein, we describe
a study protocol of two ongoing prospective, multicenter
recruitment studies, BRAINS-UK and BRAINS-South
Asia which aims to recruit 1500 highly characterised
European Caucasian stroke patients from the United
Kingdom and 1500 South Asians stroke patients from
UK, India and Sri Lanka respectively from participating
centres across the three countries. Both case control
cohorts will contribute to a combined hypothesis-free
genome wide association study (GWAS) approach in
identifying novel gene markers of stroke in European
Caucasians and South Asians from UK, India and Sri
Lanka. BRAINS will be invaluable for future candidate-
gene, GWAS and whole genome sequencing studies to
identify the genetic associations of all forms of cerebro-
vascular disease including transient ischemic attacks
(TIA), ischemic and hemorrhagic strokes. We aim to
gain a much better understanding of the genetic differ-
ences between South Asians and the European Cauca-
sian population. BRAINS uses similar definitions of
stroke and stroke classification as the successfully
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SWISS studies [2,3].
S o u t hA s i a n sf r o mt h eI n d i a ns u b - c o n t i n e n tf o r mt h e
second largest ethnic group in the world and make up
some 20% of the world’s population whereas Caucasian
Europeans constitute about 13%. Both ancestral popula-
tions have a genetically stratified structure [4,5] which
has led to the wide belief that genetic underpinnings of
disease in ethnic populations differ. This is supported by
population-based and case-control studies that have
demonstrated significant differences in incidence and
prevalence in stroke between ethnic groups that are
only partly accounted for by differences in environment
[6-10]. A number of modifiable risk factors have also
been shown to account for the differences between the
two populations including age, sex, hypertension, dia-
betes and prevalence of prior disease [11]. It is recog-
nized that as South Asians migrate out of their native
environments and expose themselves to new environ-
mental factors such as diet, their chances of developing
vascular disease increase greater than would be expected
in the host population [11]. These, along with other
epidemiological and molecular observations [12] suggest
that genetic effects on stroke may depend upon ethnic
background. As the burden of stroke is expected to
greatly increase in India over the next decade it is
important to characterize these genetic factors, and to
compare them with those in European populations.
Deciphering the molecular pathways underlying stroke
in different populations offers the promise of therapies
tailored to genetic (or racial) background, similar to the
recognition of racial dependency of anti-hypertension
treatment [13,14].
T h ed i a g n o s i so fs t r o k ec a nb ec o m p l e xw i t hal a r g e
number of clinical mimics and no known reliable blood
biomarkers or definitive genes to predict the risk of
developing stroke or incidence of disease. While the
majority of symptomatic strokes can be attributed to
modifiable risk factors such as hypertension, age and
prior disease [15], these factors do not explain why
some individuals are more susceptible to environmental
determinants compared to others with the same given
risk factors. A 4-fold increase in the risk of stroke in
progeny of stroke patients [16,17], clustering of ischemic
stroke in families [18] and occurrence of over 10% of
haemorrhagic strokes in patients with a prior family his-
tory of the same condition [19] lend support to genetic
factors being involved in causation of common,
‘acquired’ strokes, in addition to rarer familial stroke
syndromes such as sickle cell disease and CADASIL
which have been seen disproportionately in certain
racial groups.
Candidate-gene case-control studies have identified
multiple genetic polymorphisms associated with stroke.
The most consistent associations found are: Methylene-
tetrahydrofolate Reductase (MTHFR), Factor V Leiden
(FVL), Angiotensin-converting enzyme (ACE) and Pro-
thrombin (PT)[20]. Some genes found to be risk factors
for one subtype of stroke may be protective towards the
other, such as Factor V Leiden a known prothrombotic
risk factor for ischemic stroke but likely protective
against haemorrhagic stroke [21]. Other studies have
implicated genes MTHFR, ACE (I/D) and Apolipopro-
tein E (ApoE) e4 as risk factors for haemorrhagic stroke
in European Caucasians whereas Factor V Leiden is
shown to be protective [22]. In agreement with the
European Caucasian population, these genes have also
been implicated as risk factors for ischemic stroke in
people of Asian ethnicity (Chinese, Korean and Japa-
nese) [23]. Our group has also identified MTHFR,
Factor V Leiden and Prothrombin as genetic risk factors
of cerebral venous thrombosis (CVT) in Caucasians
adults and children [24] as well as South Asians from
India, Pakistan and Bangladesh. Collectively, the above
studies help us understand the possible molecular
mechanisms underlying stroke and provide us with our
best hope for developing population specific drugs to
combat this devastating disease.
2. Methods and Study Design
2A. Ethical consideration
Knowledge of an individual’s genetic profile can have
adverse effects on their ability to obtain health insurance,
employment [25,26] and acceptance in a social group
[27]. The BRAINS study meets all ethical standards set
by local institutional review boards and has received full
institutional ethics approval for the UK and South Asian
arms. Written informed consent will be obtained for
every proband and control. For intubated patients or
those rendered incompetent by stroke, surrogate consent,
within review board specifications, will be sought. This
will ensure that the BRAINS study is unbiased towards
discovery of genetic risk factors for across the entire
range of stroke severity. Patient details will be encrypted
and patient confidentiality protected. BRAINS investiga-
tors who have access to genetic data will be blinded to
individual personal identifiers such as names, addresses,
phone numbers and email addresses. Investigators who
have access to the personal identifiers will be blinded to
the genetic data. No subject will be told the result of
genetic testing as the individual risk profile in polygenic
disorders cannot be accurately measured. All data collec-
tion forms will be stored confidentially at the centres
from where the individuals were enrolled. Research data
and genetic test results will not be placed in the patients
clinical notes. Any future project applications to access
BRAINS from investigators will be assessed and will have
to follow strict MRC ethical guidelines [28]. A future use
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lines [2] to ascertain the appropriate use of BRAINS
DNA by an investigative group and maintain transpar-
ency in the collaborative efforts.
2B. Study population
Patients and spouse or age-matched controls will be
screened at the participating clinical centres in the
United Kingdom (London, Luton, Birmingham, Leeds,
Leicester, Airedale, Bradford, Wolverhampton and
Blackburn), India (New Delhi) and Sri Lanka (Colombo).
Detailed phenotype data will be collected in a specially
designed BRAINS data collection form. Stroke will be
confirmed with computed tomography or magnetic
resonance imaging and subtyped according to the Trial
of ORG10172 in Acute Stroke Treatment (TOAST)
classification [29]. Baseline clinical and demographic
data will also be collected. Blood samples will be col-
lected in EDTA coated plastic serological tubes from all
consenting patients and controls by means of a single
venepuncture and DNA extracted from peripheral lym-
phocytes using standard procedure and stored at -20°C.
Following genotyping the genetic data will be merged
with phenotype data (environmental risk factors, stroke
sub-type, clinical results) for analysis.
2B1. Probands (Cases)
BRAINS-UK will recruit 1500 cases of ischemic and
haemorrhagic stroke patients > 18 years of age from
specialist stroke centres around the UK. BRAINS-SA
will recruit 1500 cases of ischemic and haemorrhagic
stroke from specialist stroke centres around the India
and Sri Lanka. The project has the advantage of using
already extensively investigated patients with stroke.
There are likely to be a few sex differences in the overall
cohort but any small differences can be adjusted for.
Each patient with suspected stroke will be admitted to
the participating centre and evaluated by an in-house
neurologist according to institutional patient care guide-
lines which are based on current international standards
of patient care [30,31]. The patient evaluation includes
recording patient history (medical, socio-economic and
financial) physical examination (BP, pulse rate), CT or
magnetic resonance imaging (MR) of the head, and
laboratory testing (including lipid profile, CRP, ESR, and
Glucose). Exposure to environmental risk factors such
as smoking, alcohol and dietary habits will also be
recorded. In each participating centre patients seen in
inpatient acute stroke services will be reviewed. All pro-
bands will be identified using the following inclusion
criteria: (1) Patients should be aged > 18 years at the
time of enrolment; (2) Diagnosis of haemorrhagic or
ischemic stroke using WHO guidelines [32] confirmed
by clinical examination and imaging (CT or MRI);
(3) All patients with cerebral arteriovascular malforma-
tions and aneurysms; (4) South Asian or Caucasian eth-
nic backgrounds, and (5) Patient or relative written
informed consent. Exclusion criteria include: (1) Unable
to provide consent themselves or through surrogate,
and; (2) stroke not defined on CT or MRI. Patients with
old and recurrent stroke as well as seriously ill and/or
intubated patients will also be included in the study in
order to avoid bias against more severe forms of stroke.
2B2. Controls
Spouse/partners will be recruited as control subjects. As
they tend to arise from the same geographical popula-
tion and usually have similar exposure to environmental
determinants, spouse/partner controls are suitable for
case-control studies [33]. It is anticipated that occasion-
ally spouses/partners will not be available. However,
BRAINS is large enough to accommodate this. The use
of unrelated and unaffected siblings could also act as
suitable controls should the r eb ea n ys m a l ls h o r t f a l l
[34].B R A I N S - U Kwill recruit spouses or partners or
unrelated unaffected relatives of South Asian ancestry as
controls and BRAINS-SA will recruit 1500 spouses or
partners or unrelated unaffected relatives as controls.
Controls identified by probands will be asked to attend
a hospital appointment for a direct venepunture proce-
dure to obtain blood samples. If samples cannot be
recruited in this way then packages for blood collection
will be sent to controls identified either by the probands
or their relatives. Letters requesting that they have
blood extracted by their GP will accompany the
packages. Controls will meet the following inclusion cri-
teria: (1) should be aged > 18 years at the time of enrol-
ment; (2) no previous history of stroke, and; (3) able to
provide written consent. Spouse/partners will be identi-
fied on the inpatient acute stroke unit and stroke-free
status will be confirmed using the BRAINS question-
naire. Hospitalized patients with any medical condition
are not eligible as controls for BRAINS. Any lag in
spouses as controls will be filled by recruiting age and
sex matched community volunteers. Gender differences
will be balanced by using large numbers of sex-mixed
cases and/or sex-stratification during genetic analysis.
2C. Data collection
2C1. Interview
Each participating stroke ce n t r ew i l lh a v ead e v e l o p e d
stroke service and a stroke physician/neurologist/geriatri-
cian with an interest in stroke. A detailed interview will
be conducted by the local stroke trial coordinator/recrui-
ter with each patient or their surrogate and controls to
explain to them the aim of the study and role of their
participation. Written consent will be required to be
included in this study. Baseline clinical and demographic
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sex, ethnicity and other information will be collected.
Proband reported medical and family history will also be
recorded. Family history will not be verified indepen-
dently by study coordinators. All details of the interview
will be recorded on the BRAINS patient data collection
form.
2C2. Medical Records
Stroke research practitioners will review medical records
of patients whose primary diagnosis is stroke before
assessing eligibility for enrolment. Demographic, clinical
and imaging / laboratory data will be collected on all
patients using a standardised performa to ensure consis-
tency of data across centres. The following information
will be recorded on the case report forms: (1) Cardio-
vascular risk factors: vital signs (height, weight, blood
pressure, and temperature), age, sex, ethnic origin, past
history of hypertension and other cardiovascular disease,
diabetes, smoking status, alcohol intake (U/wk), family
history, (2) biomedical data: fasting glucose, lipids (total
and HDL-Cholesterol and triglycerides), prothrombin
time, Protein C and S, fibrinogen, plasma homocysteine
concentration, lipoprotein analysis along with other bio-
chemical markers, and; (3) imaging results: CT or MR
of the head, size and location of the symptomatic cere-
bral infarct as seen on head imaging. Carotid Doppler
will be undertaken when patients present with anterior
circulation lesions. Emergency room blood pressure and
biochemistry test results will be recorded.
2C3. Stroke characterization
A study appointed neurologist/stroke physician will con-
firm a clinical diagnosis of stroke. The time of onset will
be determined by talking to the patient and/or relatives
present at the time of its occurrence. The neurologist will
determine severity of neurological deficits within
48 hours of admission, based on the National Institute of
Health Stroke Scale (NIHSS)[35]. Diagnosis of stroke will
be confirmed using a CT scan or MRI of the brain,
performed after the onset of symptoms. Post stroke func-
tional status will be assessed using the Barthel Index [36]
within 48 hours of admission. The TOAST classification
system will be used to subtype stroke by a neurologist
that is blinded to the genetic and phenotypic data.
2C4. Patient follow-up
Patients are followed up by the study coordinators at the
centre from where they were recruited. Patients will be
telephoned after one year of recruitment to determine if
they have had another vascular event. If patients are suf-
fering from speech or cognition deficits, then history
will be recorded from spouse or relative. In the event of
mortality, cause of death will be ascertained.
2C5. Genetic data
Trained personnel at each participating centre obtain
10 ml peripheral blood samples from patients and
controls, in EDTA-coated vials using a single venepunc-
ture. Each sample is assigned a unique BRAINS reposi-
tory ID number and immediately stored at -20°C.
Archive quality high-molecular weight genomic DNA is
isolated from the peripheral lymphocytes using commer-
cially available Qiagen DNA isolation kits. As a quality
control, OD260/OD280 ratio is measured and accepted
if above 1.8. For lower OD260/OD280 ratio’s DNA sam-
ples will be repurified.
2C6. Adverse events
All adverse events and other vascular events will be
recorded by the study managers and forwarded to the
principle investigator.
2D. Outcome measures
The primary outcome of the present study is to establish
the largest DNA repository of highly phenotyped stroke
patients of mainly South Asian descent. We aim to
recruit 1500 stroke patients from BRAINS-UK and 3000
subjects (1500 cases) from BRAINS-SA. The secondary
outcome is to identify novel gene loci associated with
different types of stroke. Stroke patients will be com-
pared with controls to determine the frequency and dis-
tribution of these susceptibility loci. Other important
outcome measures include association of gene poly-
morphisms with stroke subtypes, ethnic groups and dif-
ferent environmental factors such as hypertension,
diabetes and smoking.
2E.Data Analysis
BRAINS is a population-based case control study that
will allow a hypothesis free genome-wide association
(GWA) approach to identify genetic risk factors asso-
ciated with stroke in European Caucasians and South
Asians. Tests for Hardy-Weinberg equilibrium will be
conducted separately for cases and controls. Genotypic
analyses will consider allele, dominant, recessive and
additive genetic models. Odds ratios will be determined
using logistic regression analyses and the significance of
association will be determined using the Chi-square or
Fisher-exact test for allele, dominant and recessive
genetic models.
2E1. Sample size and power
BRAINS-UK
All estimates of power are based on a meta-analysis of
the ACE/ID polymorphism in stroke that showed a RR
of 1.3 [37]. For the study as a whole we have ~ 1500
cases with a similar number of controls, giving us 90%
power to detect a relative risk (RR) of 1.29 at p < 0.0001
with a population allele frequency of 0.2 (which would
be appropriate for 100 candidate genes). For an allele
f r e q u e n c yo f0 . 2a n daR Ro f1 . 3 3am o r es t r i n g e n t
p value of < 0.00001 is achieved at the same 90% power.
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cases and 430 controls allows us to detect a 1.5 RR with
an allele frequency of 0.2 at a p-value of 0.01, with 80%
power.
BRAINS-SA
We intend to enrol over 3000 subjects into the study over
a 3 year period. Based on the current number of patients
seen with radiologically confirmed ischemic stroke of 500
per annum this should be a readily achievable target by
the Indian and Sri Lankan arms within the specified time
frame. This stand alone case-control study of 1500 cases
and 1500 controls provides ~90% power for an OR of 1.3
at p < 0.0001. These numbers broadly hold true for gen-
ome wide association studies using the Illumina plat-
forms [38]. The power of this study not only depends on
the frequency of the ‘risk allele’ but also on the relative
risk conferred by this allele and on the chosen type-1 and
-2 errors. However, this study is powered to detect clini-
cally significant gene effects. Moreover, BRAINS can
accommodate future advances in single nucleotide poly-
morphism (SNP) technology such as second generation
whole genome sequencing [39].
3. Discussion
Stroke is a major public health burden in the UK cost-
ing the National Health Service (NHS) about £7 billion
per year in direct care costs, loss of productivity, disabil-
ity and informal costs [40]. The disease ranks as the sec-
ond largest cause of mortality and disability in the UK
after heart disease and cancer [41,42]. Stroke affects
about 130,000 people in England and Wales alone with
a higher incidence risk in people older than 75 years of
age [43]. The majority (69%) of all strokes are ischemic
whereas 19% are haemorrhagic in nature. Of the latter,
13% are classified as intracerebral haemorrhage and 6%
subarachnoid haemorrhage. However, 12% of all strokes
have an uncertain diagnosis [44]. Worldwide, stroke
ranks as the third largest cause of death after ischemic
heart disease and cancer and accounts for 3% of the
world’s disability burden [45]. The USA alone, reports
795,000 new and recurrent strokes per year [46]. India,
C h i n aa n dR u s s i ac o l l e c t i v e l ya c c o u n tf o rt h eh i g h e s t
number of stroke cases in the world, with 80% of deaths
occurring in 2005 in India from stroke alone [47]. It is
estimated that by 2050, 80% of the global burden of new
strokes of 15 million will occur in the low and middle
income countries such as India[48,49].
The BRAINS study is a dedicated genetic risk associa-
tion study with well classified inclusion and exclusion
criteria which allow recruitment of large numbers of
stroke patients and controls. The detailed repository of
information and DNA bank allows a unique opportunity
to apply both candidate gene and whole-genome
approaches to cerebrovascular disease. The latter aim
will be realised by increasing availability of SNP data-
bases and gene chips. The use of spouses as controls
allows candidate genes hypotheses to be tested quickly
using the method of allelic-association, while controlling
for environmental variability. BRAINS allows both estab-
lished and novel candidate genes (acting either indepen-
dently or with other risk genes) to be detected, which in
time, may facilitate identification of novel potential ther-
apeutic targets. This is particularly important for a dis-
ease like stroke where there are few treatment options.
Sustainability and the development of a long-term col-
laboration is a major objective to this initiative and once
the biobank is fully established it can be used as a perma-
nent international genetic resource to spawn new ideas
and answer important questions in stroke genetics, parti-
cularly those relating to genetic differences of effects as a
result of differing ancestral origins. BRAINS is uniquely
placed as the largest repository for South Asian stroke
data consisting of samples from Northern, Central and
Southern South Asia. The results from our study will
contribute to ongoing GWAS studies in stroke in under-
standing the genetic and molecular underpinnings of
stroke.
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